Genetic Technologies teams up with TGen
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Genetic Technologies Ltd (ASX:GTG), a provider of world-leading genetic risk assessment test products, has established an important Memorandum of Understanding (MoU) with TGen, a major player in the US biomedical research industry.
TGen is an Arizona-based, not-for-profit biomedical research institute dedicated to conducting ground-breaking research with life-changing results. The group examines the genetic components of common and complex diseases, including cancer, neurological disorders, infectious disease, and rare childhood disorders.
TGen is also affiliated with City of Hope in Duarte, California, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases.
This news comes on the back of promising developments regarding Genetic Technologies’ entry into China, a recent catalyst for a 20% share price surge.
Sharing technology and infrastructure
While the terms of the MoU are confidential, key features of the agreement include cooperation between Genetic Technologies and TGen in developing a commercialisation strategy and infrastructure for a suite of polygenic risk tests.
These will be made available in the US market and provide the foundation for establishing any fund-raising mechanisms which will assist in progressing the commercialisation strategy.
The infrastructure development will include the establishment of a co-managed US-based CLIA (Clinical Laboratory Improvement Amendments - 1988 US federal regulatory standards) laboratory and provision of the new test portfolio to a major US Health Provider.
In order to achieve these initial goals, Genetic Technologies and TGen will collaborate on a number of matters with a priority being the establishment of a US-based CLIA laboratory. This will involve, among other things, defining the legal and corporate structure of the collaboration.
It will also involve the transfer of Genetic Technologies’ know-how in this area.
Group Chairman Dr Paul Kasian said, "We are excited to be working with such a prestigious organisation as TGen in bringing our current and developing future polygenic risk tests to the US market".
The US based laboratory will offer GTG’s existing and future tests.
This will include oncology polygenic risk tests for breast cancer, colorectal cancer, prostate cancer and melanoma with other tests to be considered over time.
The non-oncology tests to be offered will include cardiovascular disease and diabetes.
Highlighting the benefits of working with Genetic Technologies, associate professor of TGen David Duggan said, “The portfolio of polygenic risk tests developed by GTG opens a new pathway for helping individuals make informed decisions when it comes to improved personal health and prevention”.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
